| Prof Lenka Munoz |
| University of Sydney |
| Brain Cancer |
| Therapeutic |
Key outcomes:
- The innovation has been licensed to an industry partner.
- Has since attracted more than $7.5M in research funding has been directed towards Prof. Munoz’ lab.
- Since receiving this grant, Lenka has secured tenure and been promoted to Professor.
- Was awarded a $550k development grant (NHMRC) in 2018 for preclinical development of the 2nd generation drug candidates.
- Lin BioScience funding grant, $1,200,000
- NHMRC Ideas grant, $1,100,000
- Substancial IP and out-licensing portfolio of near-oncology therapeutics she developed.
“The funding received from the Foundation came at the right time. We discovered an interesting drug molecule which effectively killed brain cancer cells, without causing toxicity to healthy cells. With the NFMRI funding we were able to delineate its mechanism of action and generate intellectual property, which was recently licensed to an industry partner. We are currently progressing our molecule towards clinical trials, hoping that soon we will be able to offer patients with fatal brain tumours an effective treatment. All this would not be possible without the generous funding received from NFMRI.”